Carlos Garcia-De Los Ríos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carlos Garcia-De Los Ríos has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Díaz-Chamorro
Department of Internal Medicine, Virgen de las Nieves University Hospital, Granada, Spain
1 shared publication - José Mario Sabio
Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Virgen de las Nieves University Hospital, Granada, Spain
1 shared publication L. Torres-Quintero
Servicio de Cardiología, Hospital Universitario Virgen de Las Nieves, Granada, Spain
1 shared publicationMarta Medina-Casado
Regional Blood Transfusional Center, Granada, Spain
1 shared publication- María del Mar del Águila García
Sección de Genética Molecular, UGC Laboratorios, Hospital Universitario Virgen de las Nieves, Granada, Spain; Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD); Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Granada, Spain; Programa de doctorado de Medicina Clínica y Salud Pública, Universidad de Granada, Granada, Spain
1 shared publication P. González-Bustos
Unidad de Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain
1 shared publication
Latest Publications
- 12 September 2022
- Published by Springer Nature in Rheumatology International
- Vol. 43 (2) , 253-263
High-sensitivity cardiac troponin I is a biomarker for increased arterial stiffness in systemic lupus erythematous women with normal kidney function
Cardiovascular disease (CVD) is a main cause of death in patients with systemic lupus erythematous (SLE). Algorithms for cardiovascular risk stratification in general population underestimate the risk for CVD in SLE. Our study aimed to determine whether serum high-sensitivity cardiac troponin I (hs-cTnI) might help to identify SLE patients with subclinical atherosclerosis. Arterial stiffness was assessed measuring the carotid-femoral pulse wave velocity (PWV) in 68 SLE women with a normal or almost normal kidney function and in 71 controls of similar characteristics. None of the participants had a history of an overt CVD. Serum hs-cTnI level was measured using the chemiluminescence method. Factors associated with an increased PWV (iPWV) were identified and multivariate analysis was performed. When detectable, patients tended to have had higher hs-cTnI levels than controls [2.9 (2.3–4.0) vs 2.4 (2.2–4.1); p = 0.098] and were more likely to have detectable hs-cTnI [50% vs 28%, odds ratio (OR) 7.0; 95% confidence interval (CI) 0.008–0.013]. Also, patients with iPWV were more likely to have detectable hs-cTnI than those with normal PWV (OR 6.4; 95% CI 0.019–0.026). In the multivariate analysis, the age at SLE diagnosis (OR 1.24; 95% CI 1.04–1.48), systolic blood pressure (OR 1.28; 95% CI 1.10–1.48) and detectable hs-cTnI level (OR 2.04; 95% CI 1.18–3.50) were independently associated with an iPWV. The negative predictive value of having an iPWV with undetectable hs-cTnI levels was 88%. Hs-cTnI may be a useful biomarker for the identification of SLE patients with iPWV as a surrogated marker of subclinical atherosclerosis. Specifically targeted prospective studies are needed to confirm this hypothesis.
- 12 September 2022
- Published by Springer Nature in Rheumatology International
- Vol. 43 (2) , 253-263
High-sensitivity cardiac troponin I is a biomarker for increased arterial stiffness in systemic lupus erythematous women with normal kidney function
Cardiovascular disease (CVD) is a main cause of death in patients with systemic lupus erythematous (SLE). Algorithms for cardiovascular risk stratification in general population underestimate the risk for CVD in SLE. Our study aimed to determine whether serum high-sensitivity cardiac troponin I (hs-cTnI) might help to identify SLE patients with subclinical atherosclerosis. Arterial stiffness was assessed measuring the carotid-femoral pulse wave velocity (PWV) in 68 SLE women with a normal or almost normal kidney function and in 71 controls of similar characteristics. None of the participants had a history of an overt CVD. Serum hs-cTnI level was measured using the chemiluminescence method. Factors associated with an increased PWV (iPWV) were identified and multivariate analysis was performed. When detectable, patients tended to have had higher hs-cTnI levels than controls [2.9 (2.3–4.0) vs 2.4 (2.2–4.1); p = 0.098] and were more likely to have detectable hs-cTnI [50% vs 28%, odds ratio (OR) 7.0; 95% confidence interval (CI) 0.008–0.013]. Also, patients with iPWV were more likely to have detectable hs-cTnI than those with normal PWV (OR 6.4; 95% CI 0.019–0.026). In the multivariate analysis, the age at SLE diagnosis (OR 1.24; 95% CI 1.04–1.48), systolic blood pressure (OR 1.28; 95% CI 1.10–1.48) and detectable hs-cTnI level (OR 2.04; 95% CI 1.18–3.50) were independently associated with an iPWV. The negative predictive value of having an iPWV with undetectable hs-cTnI levels was 88%. Hs-cTnI may be a useful biomarker for the identification of SLE patients with iPWV as a surrogated marker of subclinical atherosclerosis. Specifically targeted prospective studies are needed to confirm this hypothesis.
- 1 January 2022
- Published by Elsevier in Hipertensión y Riesgo Vascular
- Vol. 39 (1) , 46-48
Hypertension secondary to abdominal mass
Secondary arterial hypertension (HTN) can be caused by primary hyperaldosteronism, renovascular disease, sleep apnea syndrome, chronic kidney disease, drug use, etc. In addition, some urological disorders such as hydronephrosis can cause hypertension due to an increase in intraglomerular pressure that activates the renin angiotensin system.
- 1 January 2022
- Published by Elsevier in Hipertensión y Riesgo Vascular
- Vol. 39 (1) , 46-48
Hypertension secondary to abdominal mass
Secondary arterial hypertension (HTN) can be caused by primary hyperaldosteronism, renovascular disease, sleep apnea syndrome, chronic kidney disease, drug use, etc. In addition, some urological disorders such as hydronephrosis can cause hypertension due to an increase in intraglomerular pressure that activates the renin angiotensin system.